Prof Suresh Ramalingam presents data from the FLAURA trial during a press conference at the 2019 ESMO congress.
This was a trial looking at first-line osimertinib in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC) compared with older generation EGFR-TKIs.
Watch Dr Pilar Garrido's comment here.
Watch Dr Marina Garassio's comment here.
Read more about the study here.